Shire says drug candidates in its pipeline will contribute $3bn in sales by 2020. The company set out its wares at an R&D day in New York eight weeks after AbbVie pulled out of a $53bn offer for the rare disease specialist following the US Treasury's tightening of tax rules (scripintelligence.com, 16 October 2014).
Shire says drug candidates in its pipeline will contribute $3bn in sales by 2020. The company set out its wares at an R&D day in New York eight weeks after AbbVie pulled out of a $53bn offer for the rare disease specialist following the US Treasury's tightening of tax rules (scripintelligence.com, 16 October 2014).
"Shire's clear and focused strategy has enabled us to transform our pipeline with 22 programs in the clinic, the most...
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
